279 related articles for article (PubMed ID: 24990079)
1. Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X.
Jung ID; Shin SJ; Lee MG; Kang TH; Han HD; Lee SJ; Kim WS; Kim HM; Park WS; Kim HW; Yun CH; Lee EK; Wu TC; Park YM
J Immunol; 2014 Aug; 193(3):1233-45. PubMed ID: 24990079
[TBL] [Abstract][Full Text] [Related]
2. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.
Yi H; Guo C; Yu X; Gao P; Qian J; Zuo D; Manjili MH; Fisher PB; Subjeck JR; Wang XY
Cancer Res; 2011 Nov; 71(21):6611-20. PubMed ID: 21914786
[TBL] [Abstract][Full Text] [Related]
3. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
4. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
5. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist.
Jung ID; Jeong SK; Lee CM; Noh KT; Heo DR; Shin YK; Yun CH; Koh WJ; Akira S; Whang J; Kim HJ; Park WS; Shin SJ; Park YM
Cancer Res; 2011 Apr; 71(8):2858-70. PubMed ID: 21368092
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.
Okada N; Masunaga Y; Okada Y; Mizuguchi H; Iiyama S; Mori N; Sasaki A; Nakagawa S; Mayumi T; Hayakawa T; Fujita T; Yamamoto A
Gene Ther; 2003 Oct; 10(22):1891-902. PubMed ID: 14502218
[TBL] [Abstract][Full Text] [Related]
7.
Kim WS; Jung ID; Kim JS; Kim HM; Kwon KW; Park YM; Shin SJ
Front Cell Infect Microbiol; 2018; 8():95. PubMed ID: 29637049
[No Abstract] [Full Text] [Related]
8. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
9. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
[TBL] [Abstract][Full Text] [Related]
10. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
11. A potential protein adjuvant derived from Mycobacterium tuberculosis Rv0652 enhances dendritic cells-based tumor immunotherapy.
Lee SJ; Shin SJ; Lee MH; Lee MG; Kang TH; Park WS; Soh BY; Park JH; Shin YK; Kim HW; Yun CH; Jung ID; Park YM
PLoS One; 2014; 9(8):e104351. PubMed ID: 25102137
[TBL] [Abstract][Full Text] [Related]
12. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.
Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT
J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424
[TBL] [Abstract][Full Text] [Related]
13. Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory T cell suppression via IL-6-induced Foxp3 downregulation.
Bhanumathy KK; Zhang B; Ahmed KA; Qureshi M; Xie Y; Tao M; Tan X; Xiang J
Int J Mol Sci; 2014 Mar; 15(4):5508-21. PubMed ID: 24690994
[TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
15. Targeted induction of antigen expression within dendritic cells modulates antigen-specific immunity afforded by recombinant BCG.
Kong CU; Ng LG; Nambiar JK; Spratt JM; Weninger W; Triccas JA
Vaccine; 2011 Feb; 29(7):1374-81. PubMed ID: 21211591
[TBL] [Abstract][Full Text] [Related]
16. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
17. Enhanced immunity against hepatoma induced by dendritic cells pulsed with Hsp70-H22 peptide complexes and CD40L.
Gao J; Luo SM; Peng ML; Deng T
J Cancer Res Clin Oncol; 2012 Jun; 138(6):917-26. PubMed ID: 22327301
[TBL] [Abstract][Full Text] [Related]
18. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity.
He T; Tang C; Xu S; Moyana T; Xiang J
Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804
[TBL] [Abstract][Full Text] [Related]
19. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
20. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
